Novartis AG Website

Novartis AG

SWX-NOVN

Basic

  • Market Cap

    CHF 190.08B

  • EV

    CHF 206.02B

  • Shares Out

    2,040.41M

  • Revenue

    $47.73B

  • Employees

    76,057

Margins

  • Gross

    74.61%

  • EBITDA

    39.69%

  • Operating

    29.94%

  • Pre-Tax

    20.39%

  • Net

    31.94%

  • FCF

    26.5%

Returns (5Yr Avg)

  • ROA

    10.21%

  • ROTA

    52.3%

  • ROE

    22.03%

  • ROCE

    13.32%

  • ROIC

    9.07%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    CHF 99

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $9,703M

  • Net Debt

    $17.58B

  • Debt/Equity

    0.69

  • EBIT/Interest

    16.31

Growth (CAGR)

  • Rev 3Yr

    -1.46%

  • Rev 5Yr

    0.57%

  • Rev 10Yr

    -1.01%

  • Dil EPS 3Yr

    28.33%

  • Dil EPS 5Yr

    6.87%

  • Dil EPS 10Yr

    6.54%

  • Rev Fwd 2Yr

    5.79%

  • EBITDA Fwd 2Yr

    7.32%

  • EPS Fwd 2Yr

    11%

  • EPS LT Growth Est

    7.04%

Dividends

  • Yield

  • Payout

    88.66%

  • DPS

    $3.92

  • DPS Growth 3Yr

    4.94%

  • DPS Growth 5Yr

    6.65%

  • DPS Growth 10Yr

    3.6%

  • DPS Growth Fwd 2Yr

    -0.97%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Operating Revenues

47,498

48,659

42,781

42,206

45,440

46,471

Other Revenues, Total

1,179

1,239

1,193

1,255

1,220

1,262

Total Revenues

48,677

49,898

43,974

43,461

46,660

47,733

Total Revenues % Chg.

5.6%

2.5%

-11.9%

-1.2%

7.4%

14.5%

Cost of Goods Sold, Total

14,425

15,121

11,391

11,297

12,020

12,120

Gross Profit

34,252

34,777

32,583

32,164

34,640

35,613

Selling General & Admin Expenses, Total

14,369

14,197

12,756

12,143

12,489

12,438

R&D Expenses

9,402

8,980

8,259

8,425

9,011

8,673

Other Operating Expenses

1,395

1,448

605

387

498

213

Other Operating Expenses, Total

25,166

24,625

21,620

20,955

21,998

21,324

Operating Income

9,086

10,152

10,963

11,209

12,642

14,289

Interest Expense, Total

-850

-869

-787

-800

-855

-876

Interest And Investment Income

245

91

70

377

627

627

Net Interest Expenses

-605

-778

-717

-423

-228

-249

Income (Loss) On Equity Invest.

659

673

15,337

-11

-13

-40

Currency Exchange Gains (Loss)

-160

-135

-69

-184

-214

-214

Other Non Operating Income (Expenses)

-40

-34

-39

-53

17

9

EBT, Excl. Unusual Items

8,940

9,878

25,475

10,538

12,204

13,795

Restructuring Charges

-827

-1,822

-951

-956

Gain (Loss) On Sale Of Investments

38

-260

-105

-87

Gain (Loss) On Sale Of Assets

724

166

225

111

Asset Writedown

-619

-1,664

-3,088

-3,245

Legal Settlements

-170

-313

542

37

Other Unusual Items

-91

532

296

77

EBT, Incl. Unusual Items

8,940

9,878

24,530

7,177

9,123

9,732

Income Tax Expense

1,793

1,807

1,625

1,128

551

622

Earnings From Continuing Operations

7,147

8,071

22,905

6,049

8,572

9,110

Earnings Of Discontinued Operations

4,590

1,113

906

6,282

6,138

Minority Interest

-5

1

3

-4

-3

Net Income

11,732

8,072

24,021

6,955

14,850

15,245

Net Income to Common Incl Extra Items

11,732

8,072

24,021

6,955

14,850

15,245

Net Income to Common Excl. Extra Items

7,142

8,072

22,908

6,049

8,568

9,107

Total Shares Outstanding

2,265

2,256.8

2,234.9

2,119.6

2,044

2,040.4

Weighted Avg. Shares Outstanding

2,290.8

2,277

2,242.6

2,181.2

2,076.8

2,060.3

Weighted Avg. Shares Outstanding Dil

2,319

2,296

2,260

2,197

2,092

2,076

EPS

5.1

3.5

10.7

3.2

7.2

7.4

EPS Diluted

5.1

3.5

10.6

3.2

7.1

7.4

EBITDA

13,267

14,932

15,633

15,936

17,518

18,944

Effective Tax Rate

20.1%

18.3%

6.6%

15.7%

6%

6.4%